AIDS Treatment News No. 074 - February 10, 1989
John S. James
Aerosol pentamidine was already in widespread use before this treatment IND. Several different doses had been used. The new approval specifies a recommended dose (300 milligrams every four weeks), and nebulizer (Respirgard II). It recommends aerosol pentamidine for "primary" prophylaxis (i.e. for those who have never had pneumocystis) for patients who have a T- helper count under 200--as well as for anyone who has had pneumocystis already. This criterion for primary prophylaxis is based on a yet-unpublished epidemiologic study supported by NIAID (National Institute of Allergy and Infectious Diseases).
The treatment IND allows the developer to charge for the drug to recover costs; this is the first time there has been such a charge. LyphoMed is charging the same price as for intravenous use of pentamidine, $99.45 per 300 mg dose. As a result, physicians have been slow to sign up for the program, as there is some paperwork required and no price break. Also, some have chosen to stay with the doses they have been using, at least until they see the full justification or the 300 mg recommendation, data which may not be published for several months.
The new official recognition for aerosol pentamidine should make it easier to get insurance companies to pay for the treatment. (One reason for physicians to sign up for the program, instead of continuing to prescribe aerosol pentamidine as they have done before, is that Medicaid is "likely" to decide to reimburse for treatment administered under it, and if so, reimbursement will be retroactive.) Another benefit of the treatment IND is that research protocols will probably be changed to allow patients to use aerosol pentamidine, if they do not already do so. And the U.S. approval may contribute to efforts to make aerosol pentamidine available in Canada, where lack of access has been a major problem.
LyphoMed has agreed to continue trials of aerosol pentamidine for 24 months, even after full FDA approval, so some patients will receive free treatment through this study.
Physicians and patients can obtain prescription and enrollment information by calling LyphoMed's hotline, 800/727-7003, Monday through Friday 9 AM through 9 PM EST. Physicians can request an enrollment packet with forms and instructions.
890210
ATN07402
Copyright © 1989 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .